{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:38:45Z","timestamp":1784140725614,"version":"3.55.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"3-4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972814"],"award-info":[{"award-number":["81972814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Eur J Mass Spectrom (Chichester)"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Zanubrutinib (BGB-3111) belongs to the class of irreversible inhibitors of Bruton's tyrosine kinase (BTK) for treating B-cell malignancies. A validated assay with excellent sensitivity, selectivity, and simplicity is required to measure plasma concentration and investigate its pharmacokinetics. The plasma of mice containing zanubrutinib and roxithromycin (internal standard) was processed with acetonitrile for protein precipitation. Then the supernatant was analyzed by high-performance liquid chromatography coupled with a triple quadrupole mass spectrometer using electrospray ionization in the positive mode. Zanubrutinib was given to mice intragastrically at 30 mg\/kg to determine its pharmacokinetic parameters. The method was verified and showed good linearity in the range of 0.1\u2013100 ng\/mL. The method's sensitivity, accuracy, and precision were all within acceptable bounds. By this method, the pharmacokinetic profile of zanubrutinib in mouse plasma was measured.<\/jats:p>","DOI":"10.1177\/14690667221128934","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T02:20:24Z","timestamp":1663899624000},"page":"81-88","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantitative evaluation and pharmacokinetic characteristics of the irreversible BTK inhibitor zanubrutinib in mouse plasma using LC-MS\/MS"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-7510","authenticated-orcid":false,"given":"Kai","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Kou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huining","family":"You","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"},{"name":"Health Science Center, Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"bibr1-14690667221128934","volume":"17","author":"Singh SP","year":"2018","journal-title":"Mol Cancer"},{"key":"bibr2-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.09.001"},{"key":"bibr3-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1038\/nri3487"},{"key":"bibr4-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"bibr5-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr6-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"bibr7-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"bibr8-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105463"},{"key":"bibr9-14690667221128934","doi-asserted-by":"crossref","unstructured":"Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/ refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood 2015; 126: 832.","DOI":"10.1182\/blood.V126.23.832.832"},{"key":"bibr10-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"bibr11-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"bibr12-14690667221128934","first-page":"1162","author":"Retmana IA","year":"2021","journal-title":"J Chromatogr B"},{"key":"bibr13-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12605"},{"key":"bibr14-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1078023"},{"key":"bibr15-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.504"},{"key":"bibr16-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0827"},{"key":"bibr17-14690667221128934","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11782"},{"key":"bibr18-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04015-w"},{"key":"bibr19-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12948"},{"key":"bibr20-14690667221128934","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(02)00914-5"}],"container-title":["European Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667221128934","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14690667221128934","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667221128934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:04:31Z","timestamp":1777406671000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/14690667221128934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":20,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/14690667221128934"],"URL":"https:\/\/doi.org\/10.1177\/14690667221128934","relation":{},"ISSN":["1469-0667","1751-6838"],"issn-type":[{"value":"1469-0667","type":"print"},{"value":"1751-6838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}